Drug Development Linked More Closely to Diagnostics
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2004
Volume 28
Issue 10
FDA and industry discuss proposals for regulating combination diagnostics, medical devices, and pharmacogenomic-based drug products.
Articles in this issue
A Novel Freeze Pelletization Technique for Preparing Matix Pellets
Aseptic Processing: A Review of Current Industry Practice
Can Inserts Be Improved?
Analysis of a Kneading Process to Evaluate Drug Substance-Cyclodextrin Complexation
Drug Development Linked More Closely to Diagnostics
Preparation and In Vitro Characterization of Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 Using Chiral Essential Oil Components
In The Spotlight-October 2004
October 2004
Visible-Residue Limit for Cleaning Validation and its Potential Application in Pharmaceutical Research Facility
The High Price of Success
Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up
USP General Notices and General Test Chapters: Interpretations and Misinterpretations
Breaking the Barrier: Advances in Transdermal Technology
Recent Videos
Related Content
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Article
Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
